The ESMO presidential session will feature data from Destiny-Breast05 and 11.

Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.

Four more failed tiragolumab trials, including Imbrave-152, will feature.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.

So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.

But results come from a curated dataset, with no in-trial comparator.

Global data are in the same ballpark as Chinese results presented earlier this year.

A common mutation comes into play for PRMT5 inhibition.

Investors now have more reasons to doubt Harmoni's ability to back US approval.

Tolerability could decide first-line therapy in EGFRm disease.